Key Highlights
- Shares of CervoMed (CRVO) surged 32.3% during Tuesday’s premarket session following disclosure of a substantial insider purchase
- Board member Joshua Boger acquired 955,414 shares priced at $3.14 each through a June 11 transaction via private placement
- The aggregate investment totaled roughly $3 million, executed through the Joshua S. Boger 2021 Trust
- The offering structure featured combined units consisting of common stock, Series B warrants, and Series C warrants
- Analyst firm H.C. Wainwright maintains a Buy recommendation with a $25.00 target price for CRVO
Shares of CervoMed (CRVO) experienced a significant 32.3% premarket rally on Tuesday following the disclosure of a Form 4 filing that detailed a substantial stock purchase by director Joshua Boger worth several million dollars.
Acting through the Joshua S. Boger 2021 Trust, Boger acquired 955,414 shares at a price point of $3.14 per share during a June 11 transaction. The investment totaled approximately $3 million.
Prior to this filing’s disclosure, the stock had experienced downward momentum. CRVO traded at $2.48 before the announcement, representing a decline of approximately 15% during the previous week and a substantial 70% drop across the trailing six-month period.
This acquisition occurred within a broader private placement offering that CervoMed anticipates will yield approximately $10.5 million in gross capital. The arrangement was formalized through a securities purchase agreement executed on June 9, involving Boger’s trust alongside additional accredited investors.
The unit structure for the placement included one common share, one Series B warrant, and one Series C warrant per unit. Series B warrants feature an exercise price of $3.32, become exercisable immediately, and maintain validity through June 11, 2031. Series C warrants carry a $3.14 exercise price, are similarly exercisable from inception, and expire on June 11, 2027.
CEO John J. Alam also took part in the capital raise, making this a significant transaction with substantial participation from company leadership.
Updated Stake Information
After completing this transaction, Boger’s total holdings now stand at 1,795,865 shares held indirectly across two trust entities — the JSB 2021 Trust and The Amy S. Boger 2021 Trust — plus an additional 216,817 shares owned directly.
The warrant agreements contain ownership limitations. Boger and related parties are restricted from exceeding 19.99% ownership of CervoMed’s outstanding common shares when exercising the warrants. Should warrant exercise threaten to breach this threshold, alternative pre-funded warrants become available under identical restrictions.
CervoMed’s market capitalization registered at $23.42 million prior to Tuesday’s premarket movement. According to InvestingPro analysis, the stock’s fair value estimate stands at $3.40, indicating shares were trading beneath this valuation level entering Tuesday’s session.
Wall Street Perspective
H.C. Wainwright has reaffirmed its Buy stance on CRVO, maintaining a $25.00 price objective. This recommendation followed CervoMed’s presentation of Phase 2b RewinD-LB trial data for neflamapimod at the AD/PD 2026 Conference.
The ongoing trial evaluates neflamapimod’s effectiveness in treating dementia with Lewy bodies. Results from the study indicated that patients exhibiting lower plasma pTau181 concentrations experienced more pronounced clinical improvements from the therapy.
In related corporate news, CervoMed’s shareholder base approved all measures at the company’s 2026 Annual Meeting, which included the reelection of eight board directors. Boger secured reelection among those directors.
According to the Form 4 documentation, Boger’s trust maintains 1,600,117 shares, while The Amy S. Boger 2021 Trust controls 195,748 shares, with Boger serving as sole trustee for both entities.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
